Drugs / Reconyl
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06510257 | Jul → Sep 2024 | — | Dexa Medica Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07420491 | Jun → Oct 2025 | — | Dexa Medica Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reconyl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06510257 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Reconyl is a mixed extract from 4 Indonesian herbs, Vitex trifolia (Legundi), Zingiber officinale var. Amarum (Jahe Gajah), Abrus precatorius (Saga), and Phaleria macrocarpa...” NCT06510257 ↗ |